

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB2004/002893

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61M15/00 A61K9/00 A61K31/135 A61K31/485		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61M A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 03/070304 A (G W PHARMA LTD ; DAVE RAJIV BOBBY (GB)) 28 August 2003 (2003-08-28) page 8, line 33 - page 13, line 6 page 19, line 18 - page 25, line 27; figures	1-3,7,9, 22-24,35
Y	WO 02/32487 A (RIDDIFORD MARTIN PHILIP ; G W PHARMA LTD (GB); DAVE RAJIV BOBBY (GB);) 25 April 2002 (2002-04-25) abstract; claims; figures	1-13, 15-18, 22-24,35
Y	EP 0 672 416 A (EURO CELTIQUE SA) 20 September 1995 (1995-09-20) abstract; claims; example 1	1-3,7-9, 22-24,35
-/--		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.		
<input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents :		
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed		
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
Date of the actual completion of the international search 29 September 2004		Date of mailing of the international search report 01.12.2004
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer Vanttinen, H

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB2004/002893

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 03/037306 A (WHITTLE BRIAN ANTHONY ; GW PHARMA LTD (GB)) 8 May 2003 (2003-05-08) page 4, line 1 - page 8, line 36; example 2; table 1 page 22, line 29 - page 23, line 21 page 25, line 4 - page 26, line 3; claims -----	10-13, 15-18
Y	US 3 980 766 A (SHAW IRVING F ET AL) 14 September 1976 (1976-09-14) the whole document -----	4-6

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB2004/002893

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 29, 31, 32
because they relate to subject matter not required to be searched by this Authority, namely:
It is unclear which technical features form the subject-matter of claim 29, because claims 13-16 and 18-21 relate to a dispenser and claim 29 refers to a formulation of said claims. Claims 31 and 32: Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-24, 35

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-24,35

Dispenser having a reservoir and a method for making the
same

2. claims: 25-28,30,33,34

Diamorphine formulation and its use

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.1

Claims Nos.: 29,31,32

It is unclear which technical features form the subject-matter of claim 29, because claims 13-16 and 18-21 relate to a dispenser and claim 29 refers to a formulation of said claims.
Claims 31 and 32: Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB2004/002893

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 03070304	A	28-08-2003	GB	2385845 A	03-09-2003
			GB	2385846 A	03-09-2003
			CA	2475357 A1	28-08-2003
			EP	1478420 A1	24-11-2004
			WO	03070304 A1	28-08-2003
			GB	2391857 A ,B	18-02-2004

WO 0232487	A	25-04-2002	GB	2368061 A	24-04-2002
			AU	9577101 A	29-04-2002
			CA	2426101 A1	25-04-2002
			EP	1328309 A1	23-07-2003
			WO	0232487 A1	25-04-2002
			JP	2004511310 T	15-04-2004
			US	2004069798 A1	15-04-2004

EP 0672416	A	20-09-1995	EP	0654263 A1	24-05-1995
			GB	2287880 A	04-10-1995
			EP	0672416 A1	20-09-1995
			AU	694475 B2	23-07-1998
			AU	1475595 A	21-09-1995
			CA	2144500 A1	15-09-1995
			FI	951155 A	15-09-1995
			JP	8040905 A	13-02-1996
			NO	950950 A	15-09-1995
			US	5843480 A	01-12-1998
			AT	3413 U2	27-03-2000
			AT	138566 T	15-06-1996
			AT	172376 T	15-11-1998
			AT	212224 T	15-02-2002
			AT	201989 T	15-06-2001
			AU	3995797 A	18-12-1997
			AU	722358 B2	27-07-2000
			AU	5299598 A	26-03-1998
			AU	6196394 A	17-11-1994
			AU	6610594 A	12-01-1995
			AU	682223 B2	25-09-1997
			AU	7901594 A	01-06-1995
			BG	62316 B1	31-08-1999
			BG	99077 A	30-06-1995
			BG	62473 B1	30-12-1999
			BG	99078 A	28-07-1995
			BG	62429 B1	30-11-1999
			BG	99198 A	28-08-1995
			CA	2123160 A1	11-11-1994
			CA	2127166 A1	02-01-1995
			CN	1099262 A ,B	01-03-1995
			CN	1102323 A	10-05-1995
			CN	1116521 A ,B	14-02-1996
			CZ	9401093 A3	16-11-1994
			CZ	9401550 A3	18-01-1995
			CZ	9402866 A3	14-06-1995
			DE	9422335 U1	13-04-2000
			DE	69400215 D1	04-07-1996
			DE	69400215 T2	31-10-1996
			DE	69414046 D1	26-11-1998
			DE	69414046 T2	22-04-1999
			DE	69427472 D1	19-07-2001
			DE	69427472 T2	08-11-2001

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB2004/002893

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0672416	A	DE 69429710 D1	14-03-2002
		DE 69429710 T2	08-08-2002
		DE 699436 T1	10-04-1997
		DE 729751 T1	13-03-1997
		DK 624366 T3	01-07-1996
		DK 636370 T3	28-06-1999
		DK 654263 T3	29-04-2002

WO 03037306	A	08-05-2003	GB 2381450 A
			EP 1439827 A2
			WO 03037306 A2

US 3980766	A	14-09-1976	US 3885027 A

PATENT COOPERATION TREATY


PCT

REC'D 12 SEP 2005

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference SCB63535WO00		FOR FURTHER ACTION		See Form PCT/IPEA/416
International application No. PCT/GB2004/002893		International filing date (day/month/year) 06.07.2004	Priority date (day/month/year) 07.07.2003	
International Patent Classification (IPC) or national classification and IPC A61M15/00, A61K9/00, A61K31/135, A61K31/485				
Applicant GW PHARMA LIMITED et al.				
<p>1. This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 7 sheets, including this cover sheet.</p> <p>3. This report is also accompanied by ANNEXES, comprising:</p> <p>a. <input checked="" type="checkbox"/> sent to the applicant and to the International Bureau) a total of 3 sheets, as follows:</p> <p><input type="checkbox"/> sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).</p> <p><input type="checkbox"/> sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.</p> <p>b. <input type="checkbox"/> (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s)) , containing a sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).</p>				
<p>4. This report contains indications relating to the following items:</p> <p><input checked="" type="checkbox"/> Box No. I Basis of the opinion</p> <p><input type="checkbox"/> Box No. II Priority</p> <p><input checked="" type="checkbox"/> Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</p> <p><input checked="" type="checkbox"/> Box No. IV Lack of unity of invention</p> <p><input checked="" type="checkbox"/> Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</p> <p><input type="checkbox"/> Box No. VI Certain documents cited</p> <p><input checked="" type="checkbox"/> Box No. VII Certain defects in the international application</p> <p><input type="checkbox"/> Box No. VIII Certain observations on the international application</p>				
Date of submission of the demand 06.05.2005		Date of completion of this report 09.09.2005		
Name and mailing address of the International preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465		Authorized Officer Vanttinen, H Telephone No. +49 89 2399-7442		



**INTERNATIONAL PRELIMINARY REPORT
ON PATENTABILITY**

International application No.
PCT/GB2004/002893

Box No. I Basis of the report

1. With regard to the **language**, this report is based on the international application in the language in which it was filed, unless otherwise indicated under this item.
- ☐ This report is based on translations from the original language into the following language , which is the language of a translation furnished for the purposes of:
- ☐ international search (under Rules 12.3 and 23.1(b))
 - ☐ publication of the international application (under Rule 12.4)
 - ☐ international preliminary examination (under Rules 55.2 and/or 55.3)
2. With regard to the **elements*** of the international application, this report is based on *(replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report)*:

Description, Pages

1-24 as originally filed

Claims, Numbers

1-22 received on 06.05.2005 with letter of 04.05.2005

Drawings, Sheets

1/7-7/7 as originally filed

- ☐ a sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing
3. ☐ The amendments have resulted in the cancellation of:
- ☐ the description, pages
 - ☐ the claims, Nos.
 - ☐ the drawings, sheets/figs
 - ☐ the sequence listing (*specify*):
 - ☐ any table(s) related to sequence listing (*specify*):
4. ☐ This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).
- ☐ the description, pages
 - ☐ the claims, Nos.
 - ☐ the drawings, sheets/figs
 - ☐ the sequence listing (*specify*):
 - ☐ any table(s) related to sequence listing (*specify*):

* If item 4 applies, some or all of these sheets may be marked "superseded."

**INTERNATIONAL PRELIMINARY REPORT
ON PATENTABILITY**

International application No.
PCT/GB2004/002893

Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:
- ☐ the entire international application,
 - ☒ claims Nos. 17-21
because:
 - ☒ the said international application, or the said claims Nos. 18-21 relate to the following subject matter which does not require an international preliminary examination (specify):
see separate sheet
 - ☒ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. 17 are so unclear that no meaningful opinion could be formed (*specify*):
see separate sheet
 - ☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
 - ☒ no international search report has been established for the said claims Nos. 17-21
 - ☐ the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:
 - the written form ☐ has not been furnished
 - ☐ does not comply with the standard
 - the computer readable form ☐ has not been furnished
 - ☐ does not comply with the standard
 - ☐ the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comply with the technical requirements provided for in Annex C-*bis* of the Administrative Instructions.
 - ☐ See separate sheet for further details

**INTERNATIONAL PRELIMINARY REPORT
ON PATENTABILITY**

International application No.
PCT/GB2004/002893

Box No. IV Lack of unity of invention

1. ☒ In response to the invitation to restrict or pay additional fees, the applicant has:
- ☒ restricted the claims.
 - ☐ paid additional fees.
 - ☐ paid additional fees under protest.
 - ☐ neither restricted nor paid additional fees.
2. ☐ This Authority found that the requirement of unity of invention is not complied with and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.
3. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is
- ☐ complied with.
 - ☐ not complied with for the following reasons:
4. Consequently, this report has been established in respect of the following parts of the international application:
- ☒ all parts.
 - ☐ the parts relating to claims Nos. .

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes: Claims	1-16,22
	No: Claims	
Inventive step (IS)	Yes: Claims	
	No: Claims	1-16,22
Industrial applicability (IA)	Yes: Claims	1-16,22
	No: Claims	

2. Citations and explanations (Rule 70.7):

see separate sheet

Box No. VII Certain defects in the international application

The following defects in the form or contents of the international application have been noted:

see separate sheet

1 Concerning Item III

- 1.1 It is unclear which technical features form the subject-matter of claim 17, because claims 9-12 relate to a dispenser and claim 17 refers to a formulation of said claims. Consequently and because said claim has not been searched, it cannot be examined in respect of Article 33(2)-(4) PCT.
- 1.2 Claims 18-21 fall under Rule 67.1(iv), because they concern a method for treatment of the human or animal body by therapy. Consequently and because said claims have not been searched, they cannot be examined in respect of Article 33(2)-(4) PCT.

2 Concerning Item V

- 2.1 WO-A-02/32487 (D2) discloses a dispenser according to claim 1 without a mention about a "drug of abuse" contained in the reservoir. EP-A-0 672 416 (D3), WO-A-03/037306 (D4) and US-A-3 980 766 (D5) disclose that opiates and especially diamorphine or methadone may be advantageously administered orally. In the light of the combined teachings of D2 and D3, D4 or D5, it would be obvious for the skilled person to arrive at the subject-matter of claims 1-8. Thus, the subject-matters of claims 1-8 do not meet the requirement of Article 33(3) PCT.
- 2.2 In addition, the technical features and method steps of claims 14-16 and 22 are considered to be obvious from the combination of D2 and D3, the technical features of claims 9 and 10 from the combination of D2 and D4, and the technical features of claims 11-13 appear to relate merely to one of several straightforward possibilities from which the skilled person would select, in accordance with circumstances, without the exercise of inventive skill, in order to solve the problem posed. Consequently, said claims do not meet the requirement of Article 33(3) PCT.
- 2.3 Furthermore, for the entrance into the regional phase the attention of the applicant is drawn to WO-A-03/070304 (D1) which appears to disclose the subject-matters of claims 1-3, 7, 14-16 and 22 and has a priority date which is prior to the priority date of the present application.

**INTERNATIONAL PRELIMINARY
REPORT ON PATENTABILITY
(SEPARATE SHEET)**

International application No.

PCT/GB2004/002893

- 2.4 The industrial applicability (Article 33(4) PCT) of a device according to the claims 16 and 22 appears to be self-evident.

3 Concerning Item VII

The closest prior art has not been identified as required by Rule 5(a)(ii) PCT. Furthermore, the independent claims are not in the two-part form as required by Rule 6.3(b) PCT. In addition, the claims do not include reference signs in parentheses as required by Rule 6.2(b) PCT.

CLAIMS

1. A dispenser comprising a reservoir containing a plurality of dosage units each of which comprise a formulation of a controlled drug or drug of abuse, said dosage units being contained in a tamper-evident manner such that access to the dosage units in use is controlled either by the dispenser or remotely and/or is monitored either by the dispenser or remotely.
2. The dispenser as claimed in claim 1, wherein the controlled drug or drug of abuse is a class A drug in a non-intravenous formulation, as defined by The Misuse of Drugs Act 1971.
3. The dispenser as claimed in claim 1 or 2, wherein the controlled drug or drug of abuse is an opioid.
4. The dispenser as claimed in any one of the preceding claims, wherein the opioid is methadone or a pharmaceutically acceptable salt or derivative thereof.
5. The dispenser as claimed in claim 4, wherein the opioid is methadone hydrochloride.
6. The dispenser as claimed in claim 4 or claim 5, wherein the formulation is for oral delivery.
7. The dispenser as claimed in any one of claims 1 to 3, wherein the opioid is diamorphine or a pharmaceutically acceptable salt or derivative thereof.
8. The dispenser as claimed in claim 7, wherein the opioid is diamorphine hydrochloride.

9. The dispenser as claimed in claim 7 or 8, wherein the formulation is dry and suitable for nasal delivery upon mixing with an aqueous solution.
10. The dispenser as claimed in claim 9, wherein the formulation further comprises a solubility enhancer.
11. The dispenser as claimed in claim 10, wherein the solubility enhancer is one or more of caffeine, sodium benzoate and sodium salicylate.
12. The dispenser as claimed in claim 10 or claim 11, wherein the solubility enhancer comprises caffeine and sodium benzoate and / or sodium salicylate.
13. The dispenser as claimed in any one of claims 9 to 12, wherein said formulation is a freeze-dried formulation.
14. The dispenser as claimed in any preceding claim, wherein more than 1 day's supply of dosage units are contained in the dispenser.
15. A reservoir as claimed in any one of claims 1 to 14, for use in the dispenser of claim 1.
16. A method of making a dispenser as defined in any one of claims 1 to 15, comprising introducing the plurality of dosage units into the reservoir and then sealing the reservoir in the dispenser so as to render the dispenser tamper-evident.

17. A formulation as defined in any one of claims 9 to 12.

18. A controlled method of taking a drug of abuse or a controlled drug comprising administering said drug of abuse or controlled drug from a dispenser as defined in any one of claims 1 to 14.

19. A method as claimed in claim 18, wherein said drug of abuse or controlled drug is present in a formulation as defined in any one of claims 9 to 12.

20. Use of a drug of abuse or a controlled drug in the manufacture of a medicament for use in a controlled method of taking a drug of abuse or controlled drug comprising administering said drug of abuse or controlled drug from a dispenser as defined in any one of claims 1 to 14.

21. Use as claimed in claim 20, wherein said drug of abuse or controlled drug is present in a formulation as defined in any one of 9 to 12.

22. A kit of parts comprising a dispenser as claimed in any one of claims 9 to 12; and aqueous liquid for introduction into the dispenser for rendering the formulation suitable for nasal administration.

633366; NLW; NLW


PCT REQUEST

Original (for SUBMISSION)

VIII-4-1	<p>Declaration: Inventorship (only for the purposes of the designation of the United States of America) Declaration of Inventorship (Rules 4.17(iv) and 51bis.1(a)(iv)) for the purposes of the designation of the United States of America:</p>	<p>I hereby declare that I believe I am the original, first and sole (if only one inventor is listed below) or joint (if more than one inventor is listed below) inventor of the subject matter which is claimed and for which a patent is sought.</p> <p>This declaration is directed to the international application of which it forms a part (if filing declaration with application).</p> <p>I hereby declare that my residence, mailing address, and citizenship are as stated next to my name.</p> <p>I hereby state that I have reviewed and understand the contents of the above-identified international application, including the claims of said application. I have identified in the request of said application, in compliance with PCT Rule 4.10, any claim to foreign priority, and I have identified below, under the heading "Prior Applications", by application number, country or Member of the World Trade Organization, day, month, and year of filing, any application for a patent or inventor's certificate filed in a country other than the United States of America, including any PCT international application designating at least one country other than the United States of America, having a filing date before that of the application on which foreign priority is claimed.</p>
VIII-4-1-1	Prior applications:	0315861.5, GB, 07 July 2003 (07.07.2003)


PCT

Original (for SUBMISSION)

		<p>I hereby acknowledge the duty to disclose information that is known by me to be material to patentability as defined by 37 C.F.R. § 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the PCT international filing date of the continuation-in-part application.</p> <p>I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.</p>
VIII-4-1-1-1	Name (LAST, First)	WHITTLE, Brian A.
VIII-4-1-1-2	Residence: (city and either US State, if applicable, or country)	Salisbury, United Kingdom
VIII-4-1-1-3	Mailing address:	Porton Down Science Park, Salisbury, Wiltshire, SP4 0JQ, United Kingdom
VIII-4-1-1-4	Citizenship:	GB
VIII-4-1-1-5	Inventor's Signature: (if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent)	
VIII-4-1-1-6	Date: (of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)	12 July 2004

PCT

Original (for SUBMISSION)

VIII-4-1-2-1	Name (LAST, First)	DAVE, Rajiv B.
VIII-4-1-2-2	Residence: (city and either US State, if applicable, or country)	Salisbury, United Kingdom
VIII-4-1-2-3	Mailing address:	Porton Down Science Park, Salisbury, Wiltshire, SP4 0JQ, United Kingdom
VIII-4-1-2-4	Citizenship:	GB
VIII-4-1-2-5	Inventor's Signature: (if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent)	
VIII-4-1-2-6	Date (of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)	20/7/04.